Generic HIV Medication Updates

Released: 10/21/2020  

Generic HIV Medication Updates

Truvada (emtricitabine/tenofovir disoproxil fumarate)

Gilead’s Truvada is FDA approved for the treatment of HIV-1 infection in adults and pediatric patients in combination with other antiretroviral agents and preexposure prophylaxis to reduce the risk of sexually acquired HIV-1 infection in at-risk adult and adolescents. Truvada is often used in workers’ compensation for HIV-1 occupational postexposure prophylaxis in combination with other antiretrovirals.  The generic 200mg dose has been released by Teva Pharmaceuticals and is currently available.

 

Atripla (efavirenz/emtricitabine/tenofovir disoproxil fumarate)

Atripla is FDA approved to treat HIV-1 infection in adults and pediatric patients alone or in combination with other antiretrovirals. Atripla is a combination of three different antiretroviral medications. The generic is currently available.

 

Emtriva (emtricitabine)

Emtriva is FDA approved to treat HIV-1 infection in combination with other antiretroviral agents. It may be used as part of a HIV-1 occupational postexposure prophylaxis regimen. The generic formulation is currently available.

 

Symfi and Symfi Lo (efavirenz/lamivudine/tenofovir disoproxil fumarate)

Symfi is FDA approved to treat HIV-1 infection in adult and pediatric patients. The generic formulation is currently available.

The post Generic HIV Medication Updates appeared first on Carlisle Medical.